Genesem

At a glance

Genesem filed 47 disclosures in the last 12 months, including 8 insider, 4 contract and 1 issuance. The most recent key filing was on Sep 7: Worth 20.9% of last year's revenue, over about 10 months.

Revenue for 2025 was ₩56.8B, down 17.4% on 2024. Operating margin was 1.8% against 9.5% a year earlier. Debt was 70% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩30B and operating profit of ₩1.7B.

The 2025 annual report lists 159 employees with an average tenure of 4.9 years. Its 5 directors and auditors were paid ₩493.9M each on average. It paid ₩50 per common share in cash dividends, against ₩75 a year earlier (-33.3%). 한복우 and related parties held 44.36% at year end.

From the 2025 annual report

Staff: 159 (144 men, 15 women), of whom 0 on fixed-term contracts. Directors and auditors: 5, paid ₩1.5B in total.

Dividends (common shares)

Largest shareholder

한복우 holds 38.34%; with 2 related parties the group holds 44.36% of common shares at year end.

Individuals paid ₩500M or more

Auditor: 삼덕회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

New contracts, last 12 months

1 new supply contract worth 21% of the revenue stated in the filings.

Amended amounts replace the originals. Subsidiary contracts and terminations are excluded.

Financial summary